Low SVEP1 in intrahepatic cholangiocarcinoma mediates phenotype switching-driven metastasis by Jag2/Notch1/Hes5
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-29 03:50
摘要：
SVEP1 is identified as a crucial biomarker in intrahepatic cholangiocarcinoma (ICC), with its downregulation linked to poor clinical outcomes. The study demonstrates that decreased SVEP1 expression enhances tumor cell proliferation, migration, and invasion through the activation of the Jag2/Notch1/Hes5 signaling pathway. This research underscores the potential of SVEP1 as a therapeutic target and prognostic factor in ICC, providing insights into the mechanisms driving tumor progression and metastasis.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
1.0分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.5分
technical_barrier_competition
0.5分
关键证据
SVEP1 downregulation correlates with poor prognosis in ICC patients.
The study provides experimental data showing SVEP1's role in promoting ICC cell proliferation and metastasis.
SVEP1 is identified as a potential therapeutic target in ICC.
真实性检查
否
AI评分总结
SVEP1 is identified as a crucial biomarker in intrahepatic cholangiocarcinoma (ICC), with its downregulation linked to poor clinical outcomes. The study demonstrates that decreased SVEP1 expression enhances tumor cell proliferation, migration, and invasion through the activation of the Jag2/Notch1/Hes5 signaling pathway. This research underscores the potential of SVEP1 as a therapeutic target and prognostic factor in ICC, providing insights into the mechanisms driving tumor progression and metastasis.